Adagene preclinical data demonstrates first, best-in-class new antibody candidate profiles

KUALA LUMPUR, April 11 (Bernama) -- Adagene Inc (Adagene), a company transforming the discovery and development of novel antibody-based therapies, has announced preclinical data showcasing the potential first and best-in-class profile of new antibody candidates.

According to a statement, data are being presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in New Orleans, Louisiana from April 8-13, 2022.

“We are encouraged by the preclinical data presented across four posters at AACR, showing the first and best-in-class profiles for our differentiated preclinical candidates, designed to achieve safe, potent and durable responses.

“These include ADG206, a masked, IgG1 Fc-engineered anti-CD137 therapy and ADG153, a masked anti-CD47 IgG1 antibody, and ADG138, a novel, double masked HER2xCD3 bispecific T-cell engager (TCE) for solid tumours.

“All three of these candidates are designed for improved efficacy while incorporating precision masking peptides to ensure safety of such powerful modalities,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene.

“Additionally, we are establishing a new paradigm for CD28 TCEs by targeting a unique, highly conserved epitope for local activation, and leveraging SAFEbody to ensure ultimate safety and mitigate known risks of this target.”

Key takeaways from the four posters include ADG206, an anti-CD137 agonistic POWERbody™ with tailor-made efficacy and safety profiles by strong crosslinking and tumour selective activation for single agent and combinational cancer immunotherapy.

This masked, IgG1 Fc-engineered anti-CD137 POWERbody combines conditional activation in the tumour microenvironment with strong agonistic activity through heightened FcγR-mediated crosslinking for therapeutic potential in either single agent or combination regimens.

Meanwhile, ADG153-G1 SAFEbody, a differentiated masked anti-CD47 antibody of IgG1 subclass, demonstrates in vivo anti-tumour activity consistent with enhanced ADCC/ADCP effects and significantly reduced RBC-related and antigen sink liabilities.

This masked anti-CD47 IgG1 SAFEbody is differentiated by its strong antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) activity designed to realise the full potential of anti-CD47 therapy for both hematologic and solid tumour indications.

Posters are available in the Publications section of the company’s website at www.adagene.com.

-- BERNAMA